Diplotypes of the human serotonin 1B receptor promoter predict growth hormone responses to sumatriptan in abstinent alcohol-dependent men

被引:7
|
作者
Moss, Howard B.
Hardie, Thomas L.
Dahl, John P.
Berrettini, Wade
Xu, Ke
机构
[1] Univ Penn, Sch Med, Ctr Studies Addict, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA
[3] Univ Delaware, Dept Nursing, Newark, DE USA
[4] NIAAA, Bethesda, MD USA
关键词
alcohol dependence; genetics; growth hormone; serotonin; sumatriptan;
D O I
10.1016/j.biopsych.2006.08.029
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Some studies have associated alcohol dependence (AD) with the human serotonin (5-HT)(1B) receptor (HTR1B). This investigation explored the functional responsivity of HTR1B in abstinent AD men using a sumatriptan challenge, while measuring genetic heterogeneity in the HTR1B promoter. Methods: Abstinent AD men (n = 27) and abstinent men without any alcohol use disorder (n = 19) were administered 6 mg of sumatriptan succinate, subcutaneously. Plasma samples collected over the following 2 hours were assayed for growth hormone (GH) concentrations. His DNA was genotyped for the A-161T and T-261G polymorphisms of the HTR1B promoter and diplotypes determined. Results: Integrated GH responses were predicted by interactions of AD and promoter diplotypes, as well as subject ethnicity. The final model accounted for nearly 35% of the variance in GH responses. Post hoc evaluation revealed that AD was associated with a blunting of GH secretion only among individuals with the most common HTR1B diplotype (TT/TT). Conclusions: A blunting of GH responses in abstinent AD men was observed only among those with the most common HTR1B promoter diplotype. Less common promoter diplotypes appeared protective. Controlling for genetic background is a useful augmentation of case-control pharmacological challenge strategies designed to elucidate the psychobiology of AD and other complex disorders.
引用
收藏
页码:974 / 978
页数:5
相关论文
共 10 条
  • [1] Growth hormone secretagogue receptor subtypes 1a and 1b are expressed in the human adrenal cortex
    Carraro, G
    Albertin, G
    Abudukerimu, A
    Aragona, F
    Nussdorfer, GG
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2004, 13 (02) : 295 - 298
  • [2] Functional Polymorphisms in the Serotonin 1B Receptor Gene (HTR1B) Predict Self-Reported Anger and Hostility Among Young Men
    Conner, Tarnlin S.
    Jensen, Kevin P.
    Tennen, Howard
    Furneaux, Henry M.
    Kranzler, Henry R.
    Covault, Jonathan
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2010, 153B (01) : 67 - 78
  • [3] Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors
    Barzon, L
    Pacenti, M
    Masi, G
    Stefani, AL
    Fincati, K
    Palù, G
    ONCOLOGY, 2005, 68 (4-6) : 414 - 421
  • [4] Human growth hormone receptor gene expression is regulated by Gfi-1/1b and GAGA cis-elements
    Kenth, Gurvinder
    Puzhko, Svetlana
    Goodyer, Cynthia Gates
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2011, 335 (02) : 135 - 147
  • [5] Analysis of the P3 promoter of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene in pseudohypoparathyroidism type 1b
    Minagawa, M
    Watanabe, T
    Kohno, Y
    Mochizuki, H
    Hendy, GN
    Goltzman, D
    White, JH
    Yasuda, T
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03): : 1394 - 1397
  • [6] THYROID-HORMONE RECEPTOR INHIBITS SP1-DEPENDENT TRANSCRIPTION FROM THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR PROMOTER VIA OVERLAPPING DNA-BINDING SITES
    XU, J
    THOMPSON, KL
    SHEPHARD, LB
    GILL, GN
    FASEB JOURNAL, 1993, 7 (07): : A1113 - A1113
  • [7] Cloning and characterization of the promoter regions of the human parathyroid hormone (PTH) PTH-related peptide receptor gene: Analysis of deoxyribonucleic acid from normal subjects and patients with pseudohypoparathyroidism type 1b
    Bettoun, JD
    Minagawa, M
    Kwan, MY
    Lee, HS
    Yasuda, T
    Hendy, GN
    Goltzman, D
    White, JH
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (04): : 1031 - 1040
  • [8] Capivasertib plus cyclindependent kinase 4/6 inhibitor and fulvestrant in hormone receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello292
    Hamilton, Erika
    Neven, Patrick
    Pistilli, Barbara
    Beeram, Muralidhar
    Borges, Virginia
    Campone, Mario
    Guimaraes, Jose Luiz Miranda
    Foukakis, Theodoros
    Kodahl, Annette Raskov
    Lau, Peter
    Lim, Elgene
    Lugowska, Iwona
    Rychlik, Greg
    Gresty, Christopher
    Miller, Claire
    Sommavilla, Roberto
    Sudhan, Dhivya
    Rugo, Hope
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) plus endocrine therapy (ET) in Asian patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Yap, Y. S.
    Su, F.
    Joshi, M.
    Chiu, J.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Deore, U.
    Babbar, N.
    Balbin, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S459 - S460
  • [10] TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER plus /human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
    Telli, Melinda L.
    Gawryletz, Chelsea D.
    Wei, Mei
    Patnaik, Amita
    Lu, Dongrui R.
    Mazzoletti, Marco
    Valota, Olga
    Parmar, Swapnil S.
    Tan, Weiwei
    Mukohara, Toru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)